This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rathmell, W. K. Articles by Simon, M. C. Search for Related Content PubMed PubMed Citation Articles by Rathmell, W. K. Articles by Simon, M. C.

In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations

¹ Abramson Family Cancer Research Institute and the Department of Cell and Molecular Biology, and ² Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania; and ³ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause tissue-specific tumors, with a striking genotype-phenotype correlation. Loss of VHL expression predisposes to hemangioblastoma and clear cell renal cell carcinoma, whereas specific point mutations predispose to pheochromocytoma, polycythemia, or combinations of hemangioblastoma, renal cell carcinoma, and/or pheochromocytoma. The VHL protein (pVHL) has been implicated in many cellular activities including the hypoxia response, cell cycle arrest, apoptosis, and extracellular matrix remodeling. We have expressed missense pVHL mutations in Vhl^–/– murine embryonic stem cells to test genotype-phenotype correlations in euploid cells. We first examined the ability of mutant pVHL to direct degradation of the hypoxia inducible factor (HIF) subunits HIF1 and HIF2. All mutant pVHL proteins restored proper hypoxic regulation of HIF1, although one VHL mutation (VHL^R167Q) displayed impaired binding to Elongin C. This mutation also failed to restore HIF2 regulation. In separate assays, these embryonic stem cells were used to generate teratomas in immunocompromised mice, allowing independent assessment of the effects of specific VHL mutations on tumor growth. Surprisingly, teratomas expressing the VHL^Y112H mutant protein displayed a growth disadvantage, despite restoring HIF regulation. Finally, we observed increased microvessel density in teratomas derived from Vhl^–/– as well as VHL^Y112H, VHL^R167Q, and VHL^R200W embryonic stem cells. Together, these observations support the hypothesis that pVHL plays multiple roles in the cell, and that these activities can be separated via discrete VHL point mutations. The ability to dissect specific VHL functions with missense mutations in a euploid model offers a novel opportunity to elucidate the activities of VHL as a tumor suppressor.

This article has been cited by other articles:

				C. Jimenez, M. E. Cabanillas, L. Santarpia, E. Jonasch, K. L. Kyle, E. A. Lano, S. F. Matin, R. F. Nunez, N. D. Perrier, A. Phan, et al. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 386 - 391. [Abstract] [Full Text] [PDF]

				O. Mikhaylova, M. L. Ignacak, T. J. Barankiewicz, S. V. Harbaugh, Y. Yi, P. H. Maxwell, M. Schneider, K. Van Geyte, P. Carmeliet, M. P. Revelo, et al. The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress Mol. Cell. Biol., April 15, 2008; 28(8): 2701 - 2717. [Abstract] [Full Text] [PDF]

				L. Li, L. Zhang, X. Zhang, Q. Yan, Y. A. Minamishima, A. F. Olumi, M. Mao, S. Bartz, and W. G. Kaelin Jr. Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations Mol. Cell. Biol., August 1, 2007; 27(15): 5381 - 5392. [Abstract] [Full Text] [PDF]

				C.-J. Hu, S. Iyer, A. Sataur, K. L. Covello, L. A. Chodosh, and M. C. Simon Differential Regulation of the Transcriptional Activities of Hypoxia-Inducible Factor 1 Alpha (HIF-1{alpha}) and HIF-2{alpha} in Stem Cells. Mol. Cell. Biol., May 1, 2006; 26(9): 3514 - 3526. [Abstract] [Full Text] [PDF]

				T. Hsu, Y. Adereth, N. Kose, and V. Dammai Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility J. Biol. Chem., April 28, 2006; 281(17): 12069 - 12080. [Abstract] [Full Text] [PDF]

				M. W. Lensch and G. Q. Daley Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells Blood, April 1, 2006; 107(7): 2605 - 2612. [Abstract] [Full Text] [PDF]

				K. Smith, L. Gunaratnam, M. Morley, A. Franovic, K. Mekhail, and S. Lee Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2-Driven VHL-/- Renal Cancer Cancer Res., June 15, 2005; 65(12): 5221 - 5230. [Abstract] [Full Text] [PDF]